سعر انسيلاكوس 120مجم 10 اقراص 2024

Etoricoxib 120 mg tablets, a selective COX-2 inhibitor non-steroidal anti-inflammatory drug made by EVA Pharma, Egypt; 10 tablets.

• Pain and signs of inflammation associated with acute gouty arthritis (the indication for the 120 mg dose)Population: Adults and adolescents 16 years and olderelectronic medicines compendium (eMC)
• Symptomatic relief of osteoarthritisPopulation: Adults and adolescents 16 years and olderelectronic medicines compendium (eMC)
• Symptomatic relief of rheumatoid arthritisPopulation: Adults and adolescents 16 years and olderelectronic medicines compendium (eMC)

• Very common: abdominal pain. Common: alveolar osteitis, oedema/fluid retention, dizziness, headache, palpitations, arrhythmia, hypertension, bronchospasm, constipation, flatulence, gastritis, heartburn/acid reflux, diarrhoea, dyspepsia, epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer, increased ALT/AST, ecchymosis, asthenia/fatigue, flu-like disease.International label, same formulation · electronic medicines compendium (eMC)
• Serious but less frequent effects include myocardial infarction, stroke, congestive heart failure, gastrointestinal perforation, ulcers and bleeding, hepatitis, renal insufficiency, anaphylactic reactions, angioedema, and serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to etoricoxib or excipients; active peptic ulceration or active gastrointestinal bleeding; patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or allergic-type reactions after aspirin or NSAIDs including COX-2 inhibitors.International label, same formulation · electronic medicines compendium (eMC)
• Pregnancy and lactation; severe hepatic dysfunction (serum albumin below 25 g/L or Child-Pugh 10 or more); estimated creatinine clearance below 30 mL/min; children and adolescents under 16 years; inflammatory bowel disease.International label, same formulation · electronic medicines compendium (eMC)
• Congestive heart failure (NYHA II-IV); hypertension persistently above 140/90 mmHg and not adequately controlled; established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.International label, same formulation · electronic medicines compendium (eMC)

• Upper gastrointestinal complications (perforations, ulcers or bleeding), some fatal, have occurred; caution in patients at risk (elderly, concomitant NSAID or aspirin use, history of GI disease).International label, same formulation · electronic medicines compendium (eMC)
• Selective COX-2 inhibitors may be associated with a higher risk of thrombotic events (especially myocardial infarction and stroke); use the lowest effective dose for the shortest duration and treat patients with significant cardiovascular risk factors only after careful consideration.International label, same formulation · electronic medicines compendium (eMC)
• Fluid retention, oedema and hypertension may occur; blood pressure should be controlled before treatment and monitored within two weeks of starting and periodically thereafter.International label, same formulation · electronic medicines compendium (eMC)

• Warfarin and other oral anticoagulantsEtoricoxib 120 mg daily increased prothrombin time INR by about 13%; monitor INR closely when starting or changing etoricoxib.electronic medicines compendium (eMC)
• Diuretics, ACE inhibitors, angiotensin II antagonists and beta-blockersNSAIDs may reduce their antihypertensive effect; in compromised renal function the combination may further deteriorate renal function; ensure hydration and monitor renal function.electronic medicines compendium (eMC)
• Acetylsalicylic acid (aspirin)Low-dose aspirin may be used concomitantly but increases the rate of GI ulceration and complications; not a substitute for aspirin cardiovascular prophylaxis; higher aspirin doses not recommended.electronic medicines compendium (eMC)

• No clinical data on exposed pregnancies are available; animal studies have shown reproductive toxicity and the potential human risk is unknown. Etoricoxib is contraindicated in pregnancy; if a woman becomes pregnant during treatment it must be discontinued.International label, same formulation · electronic medicines compendium (eMC)
• It is not known whether etoricoxib is excreted in human milk (it is excreted in the milk of lactating rats); women using etoricoxib must not breastfeed.International label, same formulation · electronic medicines compendium (eMC)

• Etoricoxib: Orally active, selective COX-2 inhibitor within the clinical dose range; inhibits prostaglandin formation mediating pain and inflammation, with no inhibition of COX-1 (no effect on platelet function) at clinical doses.